Peanut Study

After a long wait and the approval of our IRB- we have the following announcement-

Peanut Oral Immunotherapy (OIT) Trial Riley Hospital for Children at IU Health

 Currently there is only one treatment program for a food allergy. That treatment is avoidance. There are no other therapies approved other than that of avoiding the food that has caused an allergic reaction to a food to which allergic sensitization has been shown by a test.

Riley Hospital for Children at IU Health has been selected by ‘Aimmune Therapeutics’ as a site for their ‘Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults – the PALISADE Study. This is a phase 3 clinical study looking at the safety and efficacy of OIT for peanut allergy.

The inclusion criteria include;

  • Age 4-55 years
  • A clinical history of allergy to peanuts
  • A positive blood test and/or skin test to peanut done within the past year
  • Symptoms with exposure up to 100 mg of peanut during a peanut challenge that will be    performed in the allergy office.

The exclusion criteria include;

  • A history of cardiovascular disease
  • A history of a severe life-threatening anaphylactic reaction within 60 days of the food challenge
  • A history of a chronic health condition (other than asthma, atopic dermatitis, or allergic rhinitis) that is at risk of becoming unstable
  • A history of eosinophilic esophagitis

The study will be conducted at IU Health North, Carmel.

For more information on this study please call 317-944-3380 and ask for the study coordinator for Dr. Leickly’s OIT trial.

 

Frederick E. Leickly, MD, MPH

Professor of Clinical Pediatrics

Director of Allergy Clinical Services

 

Riley Children’s Specialists

11725 N. Illinois St., Suite 450

Carmel, Indiana 46032

 

March 15, 2016 · fleickly · No Comments
Tags: , ,  · Posted in: Food Allergies, Peanut Oral Immunotherapy, Uncategorized

Leave a Reply

You must be logged in to post a comment.